CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00074165
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:05.061069+00:00
Published At: 2011-11-16T00:00:00+00:00
Record Updated At: 2023-07-06
Results Posted At: 2011-11-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Brain and Central Nervous System Tumors", "Drug/Agent Toxicity by Tissue/Organ", "Lymphoma", "Thrombocytopenia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-07-06"
protocolSection.identificationModule.nctId: "NCT00074165"
protocolSection.identificationModule.officialTitle: "A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2011-11-16"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.